

INFORME DE BÚSQUEDA DE PATENTES
--

N° de solicitud: NC20170006222

CRITERIOS PARA LA BÚSQUEDA (anexar pantallazo o reporte en PDF, junto con los boléanos utilizados**)

Palabras clave utilizadas	ranitidine and bismuth and sucralfate and micronized micronization of api
----------------------------------	--

CLASIFICACIONES UTILIZADAS PARA LA BÚSQUEDA	CIP: A61K 31/34, A61K 31/70, A61K 33/36, A61K 9/20, A61K 9/28 CPC
--	--

DOCUMENTOS CONSIDERADOS RELEVANTES (documentos patentes, literatura no patente, etc...)
--

Informes/Base de datos	N° de solicitud/ Autor*	Fecha de Publicación/Presentación (DD/MM/AAAA)	Reiv. afectadas (con indicación, si procede, de las partes relevantes)	Categoría especiales de los documentos citados**
SIPI	-	-	-	-
EPO	KR970006083	23/04/1997	-	A
	KR100453179	15/10/2004	-	A
	JP2006076956	23/03/2006	-	A
	KR20110105223	26/09/2011	-	A
	US4990610	5/02/1991	-	A
Orbit	WO200078307	28/12/2000	1 – 19 (Pág. 10 a 14, Ej. 1 a 4)	Y
Google academico	Art. 1*	14/03/2014	1 – 19 (Título, Introducción, Pág. 222)	Y

** Categorías especiales de documentos citados:

“A” documento que define el estado general de la técnica no considerado como particularmente relevante. “E” solicitud de patente o patente anterior pero publicada en la fecha de presentación internacional o en fecha posterior. “P” documento publicado antes de la fecha de presentación internacional pero con posterioridad a la fecha de prioridad reivindicada.	“X” documento particularmente relevante; la invención reivindicada no puede considerarse nueva o que implique una actividad inventiva por referencia al documento aisladamente considerado. “Y” documento particularmente relevante; la invención reivindicada no puede considerarse que implique una actividad inventiva cuando el documento se asocia a otro u otros documentos de la misma naturaleza, cuya combinación resulta evidente para un experto en la materia.
--	--

Literatura no patente	*Olusanmi, Dolapo, et al. "A control strategy for bioavailability enhancement by size reduction: effect of micronization conditions on the bulk, surface and blending characteristics of an active pharmaceutical ingredient." <i>Powder Technology</i> 258 (2014): 222-233.
Fecha del reporte de búsqueda:	01/07/2018

BUSQUEDA EN SIPI

3 Casos asociados

Expediente No.	Título
☐  NC2017/0006222	COMPOSICIÓN FARMACÉUTICA PARA EL TRATAMIENTO DE ENFERMEDADES GASTROINTESTINALES
☐  NC2017/0010539	DERIVADOS DE 4-METOXI-PIRROL NOVEDOSOS O SALES DE LOS MISMOS Y COMPOSICIÓN FARMACÉUTICA QUE COMPRENDE LOS MISMOS
☐  NC2018/0005064	BLOQUEADOR DEL CANAL DE SODIO
Seleccionar todo - Ninguno Mostrar / Ocultar columnas 	

8 Casos asociados

Expediente No.	Título
☐  02087104	COMPOSICIONES FORMADORAS DE PELICULA QUE CONTIENEN SUCRALOSA
☐  14210001	COMPOSICIONES TÓPICAS QUE COMPREDEN FIPRONILO, PERMETRINA, N-METILPIRROLIDONA Y TRIGLICERIDOS DE ÁCIDOS CÁPRICO/CAPRÍLICO PARA REPELER Y TRATAR ECTOPARASITOS EN MAMÍFEROS
☐  15140496	COMPUESTOS ANTIHELMÍNTICOS Y COMPOSICIONES QUE COMPRENDEN ANILLOS BICÍCLICOS AROMÁTICOS O HETEROAROMÁTICOS
☐  16143378	COMPUESTOS DE ISOXAZOLINA ANTIPARASITARIOS Y PESTICIDAS
☐  NC2016/0000937	FORMULACIÓN DE SUMINISTRO TÓPICO
☐  NC2017/0005500	MÉTODO PARA LA PRODUCCIÓN DE UN SISTEMA DE ADMINISTRACIÓN FARMACÉUTICA
☐  NC2017/0006222	COMPOSICIÓN FARMACÉUTICA PARA EL TRATAMIENTO DE ENFERMEDADES GASTROINTESTINALES
☐  NC2018/0003465	MÉTODOS Y COMPOSICIONES PARA TRATAR AFECCIONES ASOCIADAS CON RESPUESTAS INFLAMATORIAS ANORMALES

BUSQUEDA EN PATBASE



Menu ▾	Search ▾	History ▾	Session ▾	Folder ▾	Order	Help ▾	Logoff
--------	----------	-----------	-----------	----------	-------	--------	--------

#	Search query	Results	Options
3	1 and 2	7	View Browse Hits Optimise more...
2	micronized	5535	View Browse Hits Optimise more...
1	TAC=(ranitidine and bismuth and sucralfate)	78	View Browse Hits Optimise more...

BUSQUEDA EN ORBIT

Menu

Filter

Explorer

948 results for (ranitidine and bismuth and sucralfate)/TI/AB/IW/DESC/ODES/OBJ - Collection: FAMPAT

Display

Print

Filter options

Legal status

Alive (532)

Dead (416)

1st application year

After 2015 (61)

2011-2015 (195)

2006-2010 (227)

2001-2005 (319)

Before 2001 (146)

More...

Assignee

IPC classification

Select

#

Title

Publication number

1st App. date

Applicant/Assignee

Relevanc score

Litigation

1

Orally administrable pharmaceutical preparation having therapeutic effect on gastrointestinal disorders comprising coated **ranitidine**, **bismuth** subcitrate and **sucralfate**

Disclosed is an orally administrable pharmaceutical preparation having therapeutic effect on gastrointestinal disorders which comprises as active ingredients **ranitidine**, **bismuth** subcitrate and **sucralfate**, wherein the **ranitidine** is coated with a coating agent to have a film dissolution time ranging from 20 to 90 minutes.

WO200078307

1999-06-21

DAEWOONG*

100 %

2

A pharmaceutical composition for treating gastrointestinal diseases

The present invention provides a pharmaceutical composition for treating gastrointestinal diseases comprising **ranitidine**, **sucralfate** and **bismuth** subcitrate as active ingredients and a preparation method thereof. According to the present invention, when a combination drug of **ranitidine**, **sucralfate** and **bismuth** subcitrate is prepared, it is possible to address a hygroscopicity problem of **ranitidine** and increase formulation stability and drug bioavailability by controlling particle sizes of **sucralfate** and **bismuth** subcitrate.

WO2016122226

2016-01-27

DAEWOONG*

100 %

3

Sucralfate-colloidal **bismuth** pectin compound pharmaceutical tablets and preparation method thereof

The invention discloses **sucralfate**-colloidal **bismuth** pectin compound pharmaceutical tablets and a preparation method thereof. The **sucralfate**-colloidal **bismuth** pectin compound pharmaceutical tablets are prepared from, by weight, 20-60 parts of colloidal **bismuth** pectin (in **bismuth**), 10-20 parts of **sucralfate** (in aluminum), 30-40 parts of a belladonna extract, 20-40 parts of a milkvetch root extract, 20-40 parts of a largehead atractylodes rhizome extract, 20-40 parts of a radix saposhnikovia extract, 50-80 parts of a radix isatidis extract, 25-30 parts of a coating agent, 3-5 parts of a disintegrating agent, 15-30 parts of a bonding agent, 2-3 parts of an excipient and 0.1-0.2 part of a corrective agent. According to the **sucralfate** colloidal **bismuth** pectin compound pharmaceutical tablets, by cooperatively using colloidal **bismuth** pectin and **sucralfate**, protection on the gastric mucosa is enhanced, and the pharmacological efficacy is improved, the traditional Chinese medicine extracts serve as an antibacterial and antiviral agent and can achieve the immunity regulating effect, enhance the immunity of the organism and decrease the disease relapse rate.

组别	崩解度 (%)	平均粒径 (μm)	分散性 (%)
实施例 1	85	0.5	80
实施例 2	88	0.5	78
实施例 3	89	0.5	82

CN105920195

2016-05-27

ZHENGZHOU SIBIAN TECHNOLOGY*

100 %

4

Medicated compositions containing **sucralfate** and processes for their production

There are disclosed novel medicated compositions useful in treating a wide variety of disorders. The novel compositions comprise **sucralfate** and a therapeutically effective amount of a medicament. In a preferred embodiment, the medicament is selected from the group consisting of antacids, antilucer medicaments, gastro-unstable medicaments, and medicaments which are normally administered in divided doses two or more times daily. Such medicated compositions are useful in treating various disorders by providing a mucous membrane adherent protective gel in the stomach having the medicament entrapped therein. The novel medicated compositions may be utilized in a wide variety of pharmaceutical products. This invention also relates to methods by which these medicated compositions and pharmaceutical products may be prepared.

IE902129

1990-03-01

PFIZER*

100 %

5

A pharmaceutical composition for treating gastrointestinal diseases

The present invention provides a pharmaceutical composition for treating gastrointestinal diseases comprising **ranitidine**, **sucralfate** and **bismuth** subcitrate as active ingredients and a preparation method thereof. According to the present invention when a combination drug of **ranitidine**, **sucralfate** and **bismuth** subcitrate is prepared it is possible to address a hygroscopicity problem of **ranitidine** and increase formulation stability and drug bioavailability by controlling particle sizes of **sucralfate** and **bismuth** subcitrate.

IN201737026464

2017-07-26

DAEWOONG*

99 %

REPLACEMENT

SECTION is not Present

Cette Section est Absente

BUSQUEDA EN GOOGLE ACADEMICO



micronization of api



Académico Página 2 de aproximadamente 2.730 resultados (0,05 s)

Sugerencia: Buscar solo resultados en **español**. Puedes especificar el idioma de búsqueda en [Configuración de Google Académico](#)..

Review and analysis of present status of the **micronization** of Chinese traditional medicine

YH Xu, NS Wang - Zhongguo Zhong yao za zhi= Zhongguo ..., 2004 - europepmc.org

... [Review and analysis of present status of the **micronization** of Chinese traditional medicine] ...

Abstract. **Micronization** is one of the methods to improve the solubility and bioavailability of drug, the **micronization** of TCM is a new technology of TCM modernization ...

☆ Citado por 6 Artículos relacionados Las 3 versiones

Fabrication of micron level particles of amoxicillin by rapid expansion of supercritical solution

AZ Hezave, F Esmailzadeh - Journal of Dispersion Science and ..., 2012 - Taylor & Francis

... **Micronization** of API using supercritical fluid (SCF) especially carbon dioxide (CO₂)

technology involves much simpler steps that can eliminate many disadvantages of the traditional processes. This novel process has been reviewed ...

☆ Citado por 9 Artículos relacionados Las 2 versiones

Evaluation of the impact of sodium lauryl sulfate source variability on solid oral dosage form development

D Qiang, JA Gunn, L Schultz, ZJ Li - Drug development and ..., 2010 - Taylor & Francis

... After **micronization**, the SLS particle morphology from the two vendors was similar. Significant reduction in particle size was achieved via **micronization** ... The PSD of the API was also reduced by **micronization**, c90 from 51.3 to 6.14 µm, as shown in Figure 7 ...

☆ Citado por 9 Artículos relacionados Las 3 versiones

A control strategy for bioavailability enhancement by size reduction: effect of **micronization** conditions on the bulk, surface and blending characteristics of an active ...

D Olusanmi, D Jayawickrama, D Bu, G McGeorge... - Powder Technology, 2014 - Elsevier

... Highlights. • The effect of varying **micronization** conditions on an API is investigated. • ... This paper demonstrates the effect of varying **micronization** conditions on an API for which **micronization** is deemed necessary to ensure consistent drug delivery after human administration ...

☆ Citado por 18 Artículos relacionados Las 4 versiones

Developing an environmentally benign process for the production of microparticles: Amphiphilic crystallization

D Murnane, C Marriott, GP Martin - European Journal of Pharmaceutics and ..., 2008 - Elsevier

... of particles [15]. **Micronization** of API crystals has been demonstrated to introduce amorphous character into the resultant particles as a result of a solid-state transition to a metastable phase [16–19]. Polymorphic transitions have ...